Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Paclitaxel in R/M HNSCC (NIVOTAX)
NCT04282109Phase 2Completed
- Start
- Jun 2020
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab in head and neck squamous cell carcinoma (HNSCC). Started Jun 2020; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04282109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04282109.